The name of the company has been changed from Laurel Organics Limited to Kimia Biosciences Limited with effect from 04-01-2019 pursuant to the Scheme of Arrangement for Amalgamation of Kimia Biosciences Limited-Transferor Company-with Laurel Organics Limited -Transferee Company-as per the approval and Order of Honrable NCLT Chandigarh.
+91-11-4706 3600

Obeticholic Acid

Obeticholic Acid

General Information :

Obeticholic acid, is a semi-synthetic bile acid analogue which has the chemical structure 6α-ethyl-chenodeoxycholic acid. It is used as a drug to treat primary biliary cholangitis, and is undergoing development for several other liver diseases and related disorders.Approval is limited to monotherapy in patient's who are intolerant to ursodeoxycholic acid, or in combination with ursodeoxycholic acid in adults who have not responded adequately to ursodeoxyholic acid alone. 1 Obeticholic acid given orally, binds to the farnesoid X receptor (FXR), a receptor found in the nucleus of cells in the liver and intestine. FXR is a key regulator of bile acid metabolic pathways. Obeticholic acid increases bile flow from the liver and suppresses bile acid production in the liver, thus reducing the exposure of the liver to toxic levels of bile acids.

Therapeutic Category –

Obeticholic Acid is act as Gastrointestinal Agent.

Product Characteristics:


(4R)-4-[(3R,5S,6S,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid


Molecular Formula:


Molecular Weight :

420.6252 g/mol

Molecular Structure:

Mechanism of Action:

Obeticholic acid (also known as INT-747), is a potent, orally bioavailable farnesoid X receptor (FXR) agonist. The key role of the farnesoid X receptor (FXR) as a regulator of bile and cholesterol metabolism in the liver, with preclinical data from numerous studies providing strong rationale for the advancement of FXR agonists as hepatoprotective therapeutics in chronic liver disease.